🇺🇸 Bimatoprost (SR) in United States

FDA authorised Bimatoprost (SR) on 4 March 2020

Marketing authorisation

FDA — authorised 4 March 2020

  • Application: NDA211911
  • Marketing authorisation holder: ABBVIE
  • Local brand name: DURYSTA
  • Indication: IMPLANT — OPHTHALMIC
  • Status: approved

Read official source →

Bimatoprost (SR) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Ophthalmology approved in United States

Frequently asked questions

Is Bimatoprost (SR) approved in United States?

Yes. FDA authorised it on 4 March 2020.

Who is the marketing authorisation holder for Bimatoprost (SR) in United States?

ABBVIE holds the US marketing authorisation.